{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/bacterial-vaginosis/background-information/prevalence/","result":{"pageContext":{"chapter":{"id":"276cab7f-4264-59d9-8986-e8de8d64e45e","slug":"prevalence","fullItemName":"Prevalence","depth":2,"htmlHeader":"<!-- begin field 0713b3d5-7e8b-44e4-8894-a91100dff80e --><h2>How common is it?</h2><!-- end field 0713b3d5-7e8b-44e4-8894-a91100dff80e -->","summary":"","htmlStringContent":"<!-- begin item 40bee2dd-afec-4076-bcc3-a91100dff59a --><!-- begin field d339e2d8-a873-48f3-8d3c-a91100dff80e --><ul><li><strong>Bacterial vaginosis (BV) is the most common cause of abnormal vaginal discharge in women of child-bearing age, but may also be encountered in perimenopausal women</strong><strong>.</strong></li><li>Reported prevalence rates include 5% in a group of asymptomatic college students, 12% in pregnant women attending an antenatal clinic in the UK, and 30% in women undergoing termination of pregnancy [<a class=\"bibliography-reference internal-reference\" href=\"/topics/bacterial-vaginosis/references/\">BASHH, 2012</a>]. It is more prevalent in Black women (45–55%) than in Caucasian women (5–15%) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/bacterial-vaginosis/references/\">Sherrard, 2018</a>].</li><li>Women who have sex with women are at increased risk for BV because they share similar lactobacillary types and are more likely to have concordant vaginal flora patterns [<a class=\"bibliography-reference internal-reference\" href=\"/topics/bacterial-vaginosis/references/\">Sherrard, 2018</a>].</li><li>The presence of BV during pregnancy varies according to ethnicity and how often a population is screened [<a class=\"bibliography-reference internal-reference\" href=\"/topics/bacterial-vaginosis/references/\">NICE, 2017</a>]: <ul><li>In a cross-sectional study of 13,747 pregnant American women, 8.8% of White women had BV compared with 22.7% in Black women, 15.9% in Hispanic women, and 6.1% in Asian-Pacific Islander women. </li><li>In an area in northwest London, screening before 28 weeks of gestation found a BV prevalence of 12%.</li></ul></li><li>The prevalence of BV is higher amongst sexually active women than non-sexually active women, although it is not generally regarded as a sexually transmitted infection.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/bacterial-vaginosis/references/\">BASHH, 2012</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/bacterial-vaginosis/references/\">Lazaro, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/bacterial-vaginosis/references/\">Sherrard, 2018</a>]  </p><!-- end field d339e2d8-a873-48f3-8d3c-a91100dff80e --><!-- end item 40bee2dd-afec-4076-bcc3-a91100dff59a -->","topic":{"id":"865cdea2-9043-57ef-8b25-031205cdd37d","topicId":"afc41d7e-87dd-41b7-bbc7-b86b9168703c","topicName":"Bacterial vaginosis","slug":"bacterial-vaginosis","lastRevised":"Last revised in October 2018","chapters":[{"id":"f7fe1c4f-d424-53b7-9e1d-2e724534b550","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"ff6b3e14-7f5b-50db-8eee-ad227bf399c7","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"9d2f35ec-215f-5ee1-b407-2c5b68e931b0","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"06809c66-f539-5454-a18a-ff951a80494b","slug":"changes","fullItemName":"Changes"},{"id":"0872ed37-dd2a-58ae-ba58-ecd7dd9c964e","slug":"update","fullItemName":"Update"}]},{"id":"b96f10d4-f421-527a-bcaf-8e5e46afb0b5","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"7b27492c-f7b2-5bdf-8be5-596f1ad99050","slug":"goals","fullItemName":"Goals"},{"id":"8b94b860-815d-522b-b4fe-461ef978443a","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"b1dc3d72-ac27-5757-be13-e2015daa0798","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"8cef0513-bbd8-5919-961e-a28c7cfdd421","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"7bc7f747-27e8-5daa-9d10-380bdcd0f2e2","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"e58af854-9d1b-51ce-a49a-83df8540a21a","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"d6cf6c66-7d92-5d41-933f-a9a879fa36d4","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"ebdd3d77-69b1-523d-a4ac-4de1bd53fcfe","slug":"definition","fullItemName":"Definition"},{"id":"7f17b28f-8990-5777-98b2-0b0a488d883f","slug":"contributing-factors","fullItemName":"Contributing factors"},{"id":"276cab7f-4264-59d9-8986-e8de8d64e45e","slug":"prevalence","fullItemName":"Prevalence"},{"id":"9a592036-9b11-587b-8576-77aac8d2b2ef","slug":"complications","fullItemName":"Complications"}]},{"id":"a011fb71-c488-53bd-b5ca-10e92c77583a","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"b250f8fd-847f-5844-a2d6-32014c81a438","slug":"assessment","fullItemName":"Assessment"},{"id":"e655909b-34b2-55ce-8897-68a2131e1a0c","slug":"examination-investigations","fullItemName":"Examination and investigations"},{"id":"5cc72fff-2222-558d-815e-907a5a25c2ef","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"0ae8498b-179a-5f9f-8ece-c5004a1ed196","fullItemName":"Management","slug":"management","subChapters":[{"id":"c43aecb1-cb55-5433-a0ce-81481bc43060","slug":"women-who-are-not-pregnant","fullItemName":"Scenario: Women who are not pregnant"},{"id":"e17bea46-46ca-5a5a-8f23-6d2541ef18b2","slug":"women-who-are-pregnant","fullItemName":"Scenario: Women who are pregnant"}]},{"id":"ff8ddbda-8b29-5d43-ad60-5aeb14b120d3","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"39735e82-4c9f-5aa2-97c7-1496f80b7c1f","slug":"oral-metronidazole","fullItemName":"Oral metronidazole"},{"id":"5eef68f3-35a3-5708-a789-014713e8af64","slug":"intravaginal-metronidazole","fullItemName":"Intravaginal metronidazole"},{"id":"ecf84ab7-5f32-5135-a8c2-b302e217480a","slug":"intravaginal-clindamycin","fullItemName":"Intravaginal clindamycin"}]},{"id":"dbca4e81-4cb5-5161-95af-5aed06ab1909","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"bab503ee-9268-578a-957b-b6f29998ba50","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"a1542e98-52d3-5650-8f50-017cdafb6bb1","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"dddaaa3b-0dea-5b97-a24a-18f6f861a9b4","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"305419c2-e2ba-51d7-b38f-9d98fdb980ed","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"b64a9957-d6e0-5d40-9465-e092bfde8548","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"748d8b76-5aee-5fe6-898a-43bbffd5751b","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"efc1492f-d327-53ae-b257-f0f17e740c27","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"d6cf6c66-7d92-5d41-933f-a9a879fa36d4","slug":"background-information","fullItemName":"Background information"},"subChapters":[]}}},"staticQueryHashes":["3666801979"]}